ASH 2021 | Iberdomide plus dexamethasone for heavily pretreated multiple myeloma

After demonstrating marked synergy with several standard myeloma treatments in preclinical investigations, iberdomide, a novel oral cereblon E3 ligase modulator (CELMoD), was investigated in different treatment combinations in a Phase I/II study of patients with relapsed/refractory multiple myeloma. Niels van de Donk, MD, PhD, VU University Medical Center, Amsterdam, Netherlands, shares the findings from the iberdomide plus dexamethasone arm of the ongoing CC-220-MM-001 trial (NCT02773030). After determination of the recommended Phase II dose of iberdomide when used in combination with dexamethasone, a dose expansion phase was initiated in triple-class exposed patients. At the time of data cut off, over 100 patients had been treated with iberdomide plus dexamethasone, with a median follow-up of 7.69 months. The overall response rate was 26.2%, with a clinical benefit rate of 36.4%. The combination was well tolerated, and adverse events were manageable with dose interruptions and reductions. Occurrence of grade 3-4 non-hematologic treatment emergent adverse events was infrequent. These results support the continued investigation of iberdomide-based combinations in myeloma. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.